Literature DB >> 21728296

Flueggines A and B, two new dimeric indolizidine alkaloids from Flueggea virosa.

Bing-Xin Zhao1, Ying Wang, Dong-Mei Zhang, Ren-Wang Jiang, Guo-Cai Wang, Jun-Min Shi, Xiao-Jun Huang, Wei-Min Chen, Chun-Tao Che, Wen-Cai Ye.   

Abstract

Two unprecedented C,C-linked dimeric indolizidine alkaloids, flueggines A (1) and B (2), were isolated from the twigs and leaves of Flueggea virosa. The structures and absolute configurations were elucidated by means of NMR, single-crystal X-ray diffraction, and CD analyses. Compound 1 is the first example of Securinega alkaloids bearing an isoxazolidine ring, the plausible biogenetic pathway of which is also proposed. Compound 2 exhibited growth inhibitory activity against MCF-7 and MDA-MB-231 human breast cancer cells.
© 2011 American Chemical Society

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21728296     DOI: 10.1021/ol201410z

Source DB:  PubMed          Journal:  Org Lett        ISSN: 1523-7052            Impact factor:   6.005


  4 in total

Review 1.  Indigenous Uses, Phytochemical Analysis, and Anti-Inflammatory Properties of Australian Tropical Medicinal Plants.

Authors:  Karma Yeshi; Gerry Turpin; Tenzin Jamtsho; Phurpa Wangchuk
Journal:  Molecules       Date:  2022-06-15       Impact factor: 4.927

2.  Development and validation of UPLC-PDA method for concurrent analysis of bergenin and menisdaurin in aerial parts of Flueggea virosa (Roxb. ex Willd.).

Authors:  Afzal Hussain; Perwez Alam; Nasir Ali Siddiqui; Mohamed Fahad Alajmi; Md Tabish Rehman; Mohd Abul Kalam; Adnan Jathlan Al-Rehaily
Journal:  Saudi Pharm J       Date:  2018-05-22       Impact factor: 4.330

Review 3.  Unique indolizidine alkaloid securinine is a promising scaffold for the development of neuroprotective and antitumor drugs.

Authors:  Sergey Klochkov; Margarita Neganova
Journal:  RSC Adv       Date:  2021-05-26       Impact factor: 4.036

4.  Evaluation of antioxidant and antiproliferative activity of Flueggea leucopyrus Willd (katupila).

Authors:  Preethi Soysa; Irushi Shamalika De Silva; Jayantha Wijayabandara
Journal:  BMC Complement Altern Med       Date:  2014-07-30       Impact factor: 3.659

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.